Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Castle Biosciences Inc CSTL

Healthcare Diagnostics & Research
Castle Biosciences, Inc., a molecular diagnostics company, provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma, and mental health conditions. The company offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test that predicts the risk of metastasis for patients with uveal melanoma; DecisionDx-SCC, a... see more

Current News (NDAQ:CSTL)

Castle Biosciences Announces Preliminary Unaudited Fourth Quarter and Full-Year 2025 Results

GlobeNewswire 8 days ago

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 19, 2025

Landmark Study Shows Combination of Castle Biosciences' DecisionDx®-UM and PRAME Outperforms Gene Mutation Analysis in Predicting Survival Outcomes in Uveal Melanoma

GlobeNewswire December 17, 2025

Systematic Review and Meta-Analysis Confirms TissueCypher® Outperforms Traditional Pathology or Clinical Factors Alone to Identify Patients at Increased Risk of Developing Esophageal Cancer

GlobeNewswire December 12, 2025

Expert Melanoma Panel Recommends Castle Biosciences' DecisionDx®-Melanoma as a Best-Practice Tool for Managing Patients with Melanoma

GlobeNewswire December 9, 2025

Castle Biosciences Earns a Houston Chronicle Top Workplaces Award for the Fifth Consecutive Year

GlobeNewswire November 17, 2025

New Data Confirms Performance of DecisionDx®-Melanoma to Identify Patients with Less Than Five Percent Risk of Sentinel Lymph Node Positivity

GlobeNewswire November 14, 2025

Castle Biosciences to Present at the Piper Sandler 37th Annual Healthcare Conference

GlobeNewswire November 11, 2025

Castle Biosciences Reports Third Quarter 2025 Results

GlobeNewswire November 3, 2025
View More News ››

Opinion & Analysis (NDAQ:CSTL)

Castle Biosciences Shares Storm Higher After Quadrupling Q3 YoY Revenue

Streetwise Reports November 13, 2019
View More Opinion ››

Bullboard Posts (NDAQ:CSTL)

Using technical analysis for this stock.

It has completed a head and shoulders formation recently so it's a big BUY signal for me
coolfooldumbguy - August 5, 2025
View more Bullboard ››

Mullen Group Ltd

Mullen Group Ltd

Mullen Group Ltd. provides a range of trucking and logistics services in Canada and the United States. It operates through ...
View More »

Podcasts